Sage Therapeutics, Inc. (NASDAQ:SAGE) is a biopharmaceutical company focused on central nervous system disorders. Shares of Sage were up in the fourth quarter on news that the FDA and EMA (European FDA) are allowing an expedited pathway to approval for the company’s drug to treat post-partum depression. Additionally, Sage announced an expansion into other disease indications, including other types of depression, Parkinson’s and tremor. We believe Sage is poised to become a leader in its space. (Josh Riegelhaupt)
From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.
